These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524 [TBL] [Abstract][Full Text] [Related]
7. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
8. Prospects and challenges for use of CAR T cell therapies in solid tumors. Ramakrishna S; Barsan V; Mackall C Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191 [No Abstract] [Full Text] [Related]
11. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Zhang P; Zhang Y; Ji N Front Immunol; 2022; 13():927132. PubMed ID: 35874698 [TBL] [Abstract][Full Text] [Related]
12. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
13. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066 [TBL] [Abstract][Full Text] [Related]
15. CAR-T cell therapy: current limitations and potential strategies. Sterner RC; Sterner RM Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells applied to solid tumors. Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y Front Immunol; 2022; 13():984864. PubMed ID: 36389701 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. Cortés-Hernández A; Alvarez-Salazar EK; Soldevila G Methods Mol Biol; 2021; 2174():219-244. PubMed ID: 32813253 [TBL] [Abstract][Full Text] [Related]
18. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors. Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR Front Immunol; 2021; 12():738456. PubMed ID: 34721401 [TBL] [Abstract][Full Text] [Related]
19. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. Yu T; Yu SK; Xiang Y; Lu KH; Sun M Front Immunol; 2022; 13():936496. PubMed ID: 35903099 [TBL] [Abstract][Full Text] [Related]
20. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Sloas C; Gill S; Klichinsky M Front Immunol; 2021; 12():783305. PubMed ID: 34899748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]